Indaptus Therapeutics is trading at $1.75, down 5.41%, with no confirmed company-specific catalyst identified for the September 9 pre-market decline.
- Closed September 8, 2026, at $1.85 after a 51.64% regular-session surge.
- Recent coverage identified a prior 59 million-share resale filing and routine board resignation; neither directly explains today’s move.